Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS From Major Insurance Carrier
Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS From Major Insurance Carrier
-- Reimbursement at $23,900, slightly below list price --
--賠償額爲 23,900 美元，略低於標價--
-- Represents a significant milestone toward increasing accessibility of PoNS --
--代表着提高 PON 可訪問性的一個重要里程碑-
NEWTOWN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the first third-party reimbursement from a major insurance carrier for the Company's Portable Neuromodulation Stimulator (PoNS) device.
賓夕法尼亞州紐敦，2024年5月29日（GLOBE NEWSWIRE）——專注於爲平衡和步態缺陷提供新型神經調節治療方法的神經科技公司Helius Medical Technologies, Inc.（納斯達克股票代碼：HSDT）（“Helius” 或 “公司”）今天宣佈，一家主要保險公司爲該公司的便攜式神經調節刺激器（PonS）設備提供了第一筆第三方報銷。
"Securing widespread reimbursement for PoNS remains a top priority for us, and we are thrilled to announce that we've received our first third-party reimbursement for this innovative device at the list price with a 7% rebate by a major insurance carrier," said Dane Andreeff, President and Chief Executive Officer of Helius. "Following Centers for Medicare & Medicaid Services' (CMS) establishment of unique Healthcare Common Procedure Coding System codes for the PoNS mouthpiece and controller, we have been actively negotiating reimbursement with third-party payers and for patients covered by the Veterans Administration and the Department of Defense through our recent partnership with Lovell Government Services."
Helius總裁兼首席執行官Dane Andreeff表示：“確保PON的廣泛報銷仍然是我們的首要任務，我們很高興地宣佈，我們已經獲得了該創新設備的首筆第三方報銷，一家大型保險公司提供了7％的折扣。”“繼醫療保險和醫療補助服務中心（CMS）爲PonS的喉舌和控制者建立了獨特的醫療保健通用程序編碼系統代碼之後，我們一直在積極與第三方付款人以及退伍軍人管理局和國防部承保的患者通過最近與洛弗爾政府服務部的合作進行報銷談判。”
"We believe this is yet another important milestone in establishing the market pricing for PoNS as we continue to negotiate with other third-party payers and CMS. In addition, we are assisting several MS patients who have or are preparing to submit claims with other third-party payers and look forward to establishing reimbursement rates with those carriers as we move forward," concluded Andreeff.
“我們認爲，在我們繼續與其他第三方付款人和CMS進行談判的過程中，這是確定PON市場定價的又一個重要里程碑。此外，我們正在爲幾名已經或準備向其他第三方付款人提交索賠的多發性硬化症患者提供援助，並期待在我們向前邁進的過程中與這些承運人確定報銷率，” 安德烈夫總結道。
The reimbursed rate, net of a 7% rebate, results in pricing of $16,554 for the controller and $7,347 for the mouthpiece, exclusive of rounding.
扣除7％的折扣後，控制器的報銷率爲16,554美元，喉舌的定價爲7,347美元，其中不包括四捨五入。